论文部分内容阅读
目的基于真实世界,研究解毒散结胶囊治疗晚期非小细胞肺癌患者疗效及生存分析。方法收集2013年1月至2016年1月期间在我院诊断为非小细胞肺癌患者52例,采用随机数字表法随机分为观察组和对照组,两组各26例。对照组采用在进行基础治疗的基础上实施化疗方案,观察组在对照组基础上再进行解毒散结胶囊治疗。治疗2月后对近期疗效和生活质量进行评估。结果在治疗后2个月后,观察组临床获益率(69.23%)明显优于对照组(26.92%),差异有统计学意义(P<0.05);观察组呼吸频率(9.56±3.21)次/min、FEV1(2.78±0.52)V/L、VCmax(1.49±0.42)V/L,观察组显著优于对照组,差异具有统计学意义(P<0.05)。观察组治疗后SF-36评分均高于对照组,组间对比具有统计学意义(P<0.05)。结论解毒散结胶囊治疗晚期非小细胞肺癌患者具有较好的近期疗效,可改善患者生存质量,值得临床进一步推广。
Objective To study the curative effect and survival analysis of Jiedu Sanjie Capsule in the treatment of advanced non-small cell lung cancer based on the real world. Methods Fifty-two patients diagnosed as non-small cell lung cancer in our hospital from January 2013 to January 2016 were randomly divided into observation group and control group using random number table method, 26 cases in each group. The control group was treated with chemotherapy based on the basis of the implementation of the program, the observation group in the control group based on the detoxication Sanjie capsule treatment. After 2 months of treatment, the recent efficacy and quality of life were evaluated. Results After 2 months of treatment, the clinical benefit rate (69.23%) in the observation group was significantly better than that in the control group (26.92%), the difference was statistically significant (P <0.05). The respiratory rate in the observation group was 9.56 ± 3.21 / min, FEV1 (2.78 ± 0.52) V / L, VCmax (1.49 ± 0.42) V / L, the observation group was significantly better than the control group, the difference was statistically significant (P <0.05). The score of SF-36 in the observation group was higher than that in the control group, and there was significant difference between the two groups (P <0.05). Conclusion Jiedu Sanjie Capsule for patients with advanced non-small cell lung cancer has good short-term curative effect, which can improve the quality of life of patients and deserve further clinical promotion.